Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial
Phase 1
- Conditions
- The study population includes all patients aged over 18 with a neuroendocrine tumor grade I and II and a clinical indication for PRRT.Therapeutic area: Diseases [C] - Neoplasms [C04]
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Age = 18 years, Able to provide spoken and written informed consent for the trial, Histopathological confirmed neuroendocrine tumor, Fulfill the clinical criteria for PRRT, At least one soft tissue lesion > 2 cm, Aimed administered activity of 7400 MBq, ECOG score (performance status) 0-2
Exclusion Criteria
Not possible to discontinue LA-SSA for 4-6 weeks, Use of short-acting somatostatin analogues, Inability to comply to the study procedures, Factors that might affect the biodistribution (for example, indication for furosemide directly after PRRT infusion, limited fluid intake, any renal catheters, etc.), Pregnancy and lactating female patients
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method